Literature DB >> 5790273

Haemolytic disease of the newborn caused by anti-Lan antibody.

D S Smith, F Stratton, T Johnson, R Brown, P Howell, R Riches.   

Abstract

The first recorded example of anti-Lan associated with haemolytic disease of the newborn is reported. This emphasizes the importance of screening for atypical antibodies early in pregnancy, even though prophylactic use of anti-D immunoglobulin will eventually reduce the incidence of haemolytic disease due to anti-D antibody.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5790273      PMCID: PMC1983863          DOI: 10.1136/bmj.3.5662.90

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  3 in total

1.  The preparation and uses of antiglobulin reagents with special reference to complement-fixing blood group antibodies.

Authors:  F STRATTON; H H GUNSON; V I RAWLINSON
Journal:  Transfusion       Date:  1962 May-Jun       Impact factor: 3.157

2.  A second example of anti-Lan.

Authors:  A J Grindon; M H McGinniss; P D Issitt; J K Reihart; F H Allen
Journal:  Vox Sang       Date:  1968       Impact factor: 2.144

3.  Serologic tests in relation to prenatal and postnatal diagnosis of hemolytic disease of the newborn.

Authors:  F Stratton; P H Renton
Journal:  Clin Pediatr (Phila)       Date:  1967-06       Impact factor: 1.168

  3 in total
  2 in total

1.  Quantitation of Lan antigen in Lan+, Lan+(w) and Lan- phenotypes.

Authors:  Rhiannon S McBean; Brett Wilson; Yew-Wah Liew; Catherine A Hyland; Robert L Flower
Journal:  Blood Transfus       Date:  2015-02-26       Impact factor: 3.443

2.  ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis.

Authors:  Virginie Helias; Carole Saison; Bryan A Ballif; Thierry Peyrard; Junko Takahashi; Hideo Takahashi; Mitsunobu Tanaka; Jean-Charles Deybach; Hervé Puy; Maude Le Gall; Camille Sureau; Bach-Nga Pham; Pierre-Yves Le Pennec; Yoshihiko Tani; Jean-Pierre Cartron; Lionel Arnaud
Journal:  Nat Genet       Date:  2012-01-15       Impact factor: 38.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.